<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777829</url>
  </required_header>
  <id_info>
    <org_study_id>K01MH080992-01</org_study_id>
    <secondary_id>K01MH080992-01</secondary_id>
    <secondary_id>071529</secondary_id>
    <secondary_id>DNBBS 7K-TGNB</secondary_id>
    <nct_id>NCT00777829</nct_id>
    <nct_alias>NCT00773032</nct_alias>
  </id_info>
  <brief_title>Memory Consolidation in Pharmacologically Enhanced Naps</brief_title>
  <official_title>Understanding Memory Consolidation by Studying Pharmacologically Enhanced Naps.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine whether various drugs affecting sleep cycles can improve different&#xD;
      kinds of memory.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research provides evidence for strong, specific connections between sleeping and memory. This&#xD;
      research shows that sleeping is necessary for certain types of memories to form, certain&#xD;
      sleep stages lead to specific types of learning and memory consolidation, and naps are as&#xD;
      effective as night-time sleep in these learning and memory processes. Current evidence also&#xD;
      indicates that there are different types of memory and that the different types can operate&#xD;
      and develop independently. In this study, three different memory types will be examined:&#xD;
      perceptual, motor, and declarative memory. Perceptual memory is measured through the ability&#xD;
      to recognize discrete stimuli; motor memory is measured through the ability to perform&#xD;
      specific, coordinated tasks; and declarative memory is measured through the ability to recite&#xD;
      memorized information. Different stages in the sleep cycle correlate with improvements in&#xD;
      each of these memory processes. For instance, improvement of perceptual memory tasks is&#xD;
      dependent on rapid eye motion (REM) sleep; motor learning is related to sleep stage 2; and&#xD;
      declarative memory consolidation is related to short wave sleep (SWS), which includes sleep&#xD;
      stages 3 and 4.&#xD;
&#xD;
      New drugs can target specific sleep stages and increase the amount of time people spend in&#xD;
      those stages when they sleep. For example, the new prescription drug zolpidem increases time&#xD;
      spent in stage 2 during sleep, and the drug sodium oxybate increases time spent in SWS.&#xD;
      Compared to sleep impacted by either zolpidem or sodium oxybate, normal sleep has&#xD;
      proportionally more time spent in REM. This study will use medications, or their lack, to&#xD;
      manipulate how much time is spent in REM, stage 2, and SWS. The study will then examine&#xD;
      whether the percentage of sleep spent in different stages affects the learning processes&#xD;
      associated with those stages.&#xD;
&#xD;
      Participation in this study will last 6 weeks. At the outset, participants will undergo a&#xD;
      2-hour screening visit that will include a medical history, a physical examination, routine&#xD;
      lab tests, urine tests for drugs and pregnancy, an electrocardiogram, and a clinical&#xD;
      interview for mental health. Participants will also be asked to complete a series of&#xD;
      questionnaires on subjective sleep quality, sleep quantity, and daytime sleepiness.&#xD;
&#xD;
      Participants will complete five study visits, beginning 1 week from screening and separated&#xD;
      by 5 to 10 days to allow drug wash-out and recovery from effects of the previous visit. Each&#xD;
      study visit will involve an overnight stay in a sleep lab. Participants will arrive at 8 PM,&#xD;
      go to bed at 10 PM, and be awakened at 5 AM. Between 6 and 8 AM, they will undergo three&#xD;
      different tests, each corresponding to a different type of learning and memory process:&#xD;
      perceptual, motor, or declarative. The test will include recognizing a target image, typing a&#xD;
      specific finger sequence on a keyboard, and verbally recalling a list of words. Participants&#xD;
      will receive one of the study drugs or placebo at 8:30 AM and then be allowed to take a&#xD;
      90-minute nap between 9 and 11 AM. They will receive a different drug, different dosage, or&#xD;
      placebo at each study visit. Between 4 and 6 PM, they will be retested on the previous three&#xD;
      tests. While sleeping, participants will be outfitted with sensors monitoring muscle&#xD;
      activity, eye movements, brain waves, heart and lung functioning, and-on the first&#xD;
      night-breathing.&#xD;
&#xD;
      For the entire duration of the study, participants will wear an actigraph, which is a&#xD;
      wristwatch-like device that monitors sleep cycles. Participants will also be required to&#xD;
      maintain a regular sleep schedule, going to sleep and waking up in the same 2-hour window&#xD;
      each day. They will also report on sleep schedule and caffeine, alcohol, and drug use in a&#xD;
      daily sleep diary. Caffeine, alcohol, and drug use will be prohibited starting at noon on the&#xD;
      day prior to each study visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2008</start_date>
  <completion_date type="Actual">June 1, 2011</completion_date>
  <primary_completion_date type="Actual">June 1, 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacological Enhancement of Specific Sleep Parameters</measure>
    <time_frame>Two weeks</time_frame>
    <description>Number of sleep spindles comparing placebo vs active drug. We count spindles in the EEG record.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of Pharmacological Interventions With Sleep-stage-specific Memory Tasks</measure>
    <time_frame>two weeks</time_frame>
    <description>improvement on a verbal memory task in active drug. We measured the number of words recalled.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>zolpidem first, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received one dose of zolpidem for one nap, then had a one week washout period, followed by once dose of placebo for one nap.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, then zolpidem</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received one dose of placebo for one nap, then had a one week washout period, followed by once dose of zolpidem for one nap.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolpidem</intervention_name>
    <description>Participants will receive one dose of 10 mg before each nap.</description>
    <arm_group_label>Placebo first, then zolpidem</arm_group_label>
    <arm_group_label>zolpidem first, then placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive a dose of placebo before each nap.</description>
    <arm_group_label>Placebo first, then zolpidem</arm_group_label>
    <arm_group_label>zolpidem first, then placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Speaks English&#xD;
&#xD;
          -  Resides in the general San Diego community&#xD;
&#xD;
          -  Completed at least 12 years of formal education, because education may affect&#xD;
             performance on the cognitive task&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No regular sleep-wake schedule, defined as not meeting study criteria or scoring&#xD;
             between 31 and 69 on the Horne-Ostberg Morningness-Eveningness Questionnaire&#xD;
&#xD;
          -  Presence of a sleep disorder reported or detected on the questionnaires&#xD;
&#xD;
          -  Personal or immediate family (i.e., first degree relative) history of diagnosed&#xD;
             significant psychopathology&#xD;
&#xD;
          -  Personal history of head injury with loss of consciousness for more than 15 minutes or&#xD;
             with seizures&#xD;
&#xD;
          -  History of substance dependence&#xD;
&#xD;
          -  Current use of any psychotropic medications&#xD;
&#xD;
          -  Any cardiac, respiratory, or other medical condition that may affect cerebral&#xD;
             metabolism&#xD;
&#xD;
          -  Noncorrectable vision and audition impairments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara C. Mednick, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD General Clinical Research Center Laboratory for Sleep and Chronobiology (GCRC-LSC)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 20, 2008</study_first_submitted>
  <study_first_submitted_qc>October 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <results_first_submitted>July 2, 2020</results_first_submitted>
  <results_first_submitted_qc>July 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2021</results_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Sara C. Mednick</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>Nap</keyword>
  <keyword>Pharmacology</keyword>
  <keyword>Memory</keyword>
  <keyword>Visual Learning</keyword>
  <keyword>Verbal Memory</keyword>
  <keyword>Motor Learning</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zolpidem First, Then Placebo</title>
          <description>Participants received one dose of zolpidem for one nap, then had a one week washout period, followed by once dose of placebo for one nap.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Zolpidem</title>
          <description>Participants received one dose of placebo for one nap, then had a one week washout period, followed by once dose of zolpidem for one nap.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Study Orientation</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>This was a within-subjects design, so all 30 started in the participant flow, but only 28 completed all arms of the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacological Enhancement of Specific Sleep Parameters</title>
        <description>Number of sleep spindles comparing placebo vs active drug. We count spindles in the EEG record.</description>
        <time_frame>Two weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zolpidem</title>
            <description>This arm reflects all participants who received the drug (one dose of 10mg before each nap) during the entire course of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This arm reflects all participants who received the placebo (a dose of placebo before each nap) during the entire course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacological Enhancement of Specific Sleep Parameters</title>
          <description>Number of sleep spindles comparing placebo vs active drug. We count spindles in the EEG record.</description>
          <units>sleep spindles</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.5"/>
                    <measurement group_id="O2" value="1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Pharmacological Interventions With Sleep-stage-specific Memory Tasks</title>
        <description>improvement on a verbal memory task in active drug. We measured the number of words recalled.</description>
        <time_frame>two weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zolpidem</title>
            <description>This arm reflects all participants who received the drug (1 dose of 10mg before each nap) during the entire course of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This arm reflects all participants who received the placebo (1 dose of placebo before each nap) during the entire course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Pharmacological Interventions With Sleep-stage-specific Memory Tasks</title>
          <description>improvement on a verbal memory task in active drug. We measured the number of words recalled.</description>
          <units>recall of words</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="1.0"/>
                    <measurement group_id="O2" value="1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Zolpidem</title>
          <description>This arm reflects all participants who received the drug (1 dose of 10mg before each nap) during the entire course of the study.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>This arm reflects all participants who received the placebo (1 dose of placebo before each nap) during the entire course of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sara C. Mednick</name_or_title>
      <organization>UCSD</organization>
      <phone>8586423192</phone>
      <email>mednicks@uci.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

